This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Graham A. Colditz, MB, BS; Meir J. Stampfer, MD; Walter C. Willett, MD; Frank E. Speizer, MD
Brigham and Women's Hospital Channing Laboratory Boston, Mass

Charles H. Hennekens, MD; Bernard Rosner, PhD
Harvard Medical School Boston, Mass

JAMA. 1991;265(14):1825.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply. —

Dupont suggests that the increased risk of breast cancer among current users of estrogen replacement therapy may be due, in part, to greater surveillance and early detection, basing this hypothesis on our crude rates of breast cancer. As shown in Table 2 of our article, age is strongly related to use of estrogen therapy and hence confounds the simplified analysis of Dupont; using age-adjusted data, we found a 36% excess risk among current estrogen users, not a 20% excess as he claims. Further, the difference in the prevalence of mammography was 15% (64% in current estrogen users and 49% in nonusers—not 31%), and the distribution of tumor size at diagnosis was similar across categories of use of estrogen therapy (an excess of small tumors would be expected among estrogen users if our findings were an artifact). Thus, as we indicated in greater detail in our discussion, surveillance . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?